Autoimmunity: When Defence Turns on You
Your immune system’s hardest job is not attacking invaders — it is learning not to attack you. As they mature, T and B cells that would react against your own tissues are mostly deleted or disabled: in the thymus and bone marrow (“central tolerance”), backed up by regulatory T cells patrolling the body (“peripheral tolerance”). Autoimmunity is when that self-tolerance breaks and the same weapons — autoantibodies and self-reactive T cells — turn on your own organs. Press play and watch the school delete traitors; then break it, let one escape, and watch a target organ come under fire.
Try this: start on Healthy tolerance and watch self-reactive cells get deleted, then hit Tolerance breaks and Attack and watch the organ-function gauge fall while the autoantibody titer climbs — finally press Treatment and see the attack calm as the infection-risk gauge rises.
Live immune readout
What’s happening
Real vs model: the antibody cutoffs are genuine clinical reference values (anti-TPO positive above ~35 IU/mL, anti-CCP above ~20 U/mL, anti-GAD65 assay-dependent). The tolerance %, organ-function %, infection-risk gauge and cell counts are an illustrative model of the mechanism, not measurements from one patient.
The Science in Plain Language
Your immune system’s hardest job is not attacking you
An immune system that could destroy any bacterium or virus is also, in principle, powerful enough to destroy you. Every T and B cell is built by shuffling gene segments almost at random, so the body generates millions of different receptors without knowing in advance what each one will recognise. By pure chance, a large fraction of those receptors fit your own proteins. The immune system’s deepest problem is therefore not learning to attack — it is learning self-tolerance: which targets are off-limits because they are you.
Central tolerance — the thymus deletes the traitors
T cells are educated in the thymus, a gland behind your breastbone (B cells are schooled in the bone marrow). Immature T cells are marched past antigen-presenting cells that display fragments of your own proteins. A cell that binds a self-antigen too strongly is ordered to self-destruct — this is negative selection, or clonal deletion, and it is the puffs you see in the animation. A remarkable gene called AIRE lets thymus cells display “tissue-restricted” proteins — insulin, thyroid enzymes, eye proteins — that normally exist only far away, so self-reactive clones against those tissues can be caught early too. When AIRE is broken, people develop a dramatic multi-organ autoimmune disease (APECED/APS-1), which is the clinical proof that this step matters.
Peripheral tolerance — Tregs are the second line
Deletion is not perfect; some self-reactive cells always slip through into the blood. So the body keeps a second safety net in the periphery: regulatory T cells (Tregs), marked by the master gene FOXP3. Tregs actively suppress other immune cells and calm responses that start to drift toward self. When FOXP3 is mutated, the result is IPEX syndrome — severe, early autoimmunity — again showing that a single missing brake is enough to unleash the system. In the diagram, the blue Tregs patrolling the bloodstream are this peripheral tolerance.
When tolerance breaks: autoantibodies and self-reactive T cells
Autoimmunity is what happens when both nets fail for a particular target. A self-reactive T cell that should have been deleted escapes and is not suppressed; it helps B cells mature into plasma cells that pump out autoantibodies — antibodies aimed at your own molecules. Now the immune system attacks your tissue with exactly the weapons the immune-response page shows against germs: antibodies that tag targets (and can trip the complement cascade) and killer T cells that destroy them directly. The damage is real, ongoing, and self-sustaining.
Where the attack lands defines the disease
Autoimmunity is not one illness — the target decides the diagnosis, which is why the visualization lets you switch organs:
- Type 1 diabetes: T cells destroy the insulin-making beta cells of the pancreas; antibodies to GAD65, insulin and IA-2 appear, and insulin output collapses.
- Rheumatoid arthritis: the attack hits the joint synovium; anti-CCP (positive above ~20 U/mL) and rheumatoid factor are the tell-tale antibodies.
- Hashimoto’s & Graves’: both target the thyroid. In Hashimoto’s, anti-TPO antibodies accompany a gland that fails (low thyroid). In Graves’, an antibody mimics TSH and jams the gland on (overactive thyroid) — same organ, opposite result.
- Lupus (SLE): antibodies against the cell nucleus itself (ANA, anti-dsDNA) let it hit many organs at once — skin, joints, kidneys, blood.
- Multiple sclerosis: the attack strips the myelin insulation off nerves, so signals slow or fail (see how immune cells work and the nerve-signal page).
The same person can even carry more than one of these at once, because a broken tolerance mechanism is rarely perfectly specific — someone with Hashimoto’s thyroid disease is more likely than average to also develop type 1 diabetes or celiac disease. That clustering is one of the clues that these are not unrelated illnesses but different endpoints of the same underlying failure to distinguish self from non-self. Switch the target organ in the animation and you are, in effect, switching diagnoses while the mechanism on the left stays identical.
Why does tolerance break? Genes plus a trigger
It usually takes both a loaded gun and a trigger. The strongest genetic risk sits in the HLA region — the very genes that decide which fragments your immune cells “see.” Certain versions raise risk: HLA-DR4 in rheumatoid arthritis and type 1 diabetes, HLA-DQ2/DQ8 in type 1 diabetes and celiac disease. On top of that comes a trigger, and the clearest one is molecular mimicry: an infection carries a molecule that looks like one of your own proteins, so the immune response against the germ spills over onto you. The textbook example is rheumatic fever, where antibodies against the M protein of Streptococcus cross-react with heart tissue — press the Molecular mimicry button to add this trigger and watch tolerance slip.
Why women far more often?
About four out of five people with an autoimmune disease are women, and for some conditions the gap is stark — lupus runs roughly 9:1 female. The reasons are still being worked out, but they cluster around sex hormones (estrogen tends to amplify antibody responses), the fact that women carry two X chromosomes (which are rich in immune genes and can be incompletely silenced), and immune shifts around pregnancy. This is a real, reproducible pattern, not a coincidence — but it does not mean an individual man cannot get these diseases.
Treatment: turn the attack down, not up
Because the problem is an over-active, mis-aimed immune system, treatment is immunosuppression. Broad tools like glucocorticoids (prednisone) and methotrexate lower the whole response. Newer targeted biologics aim more precisely: TNF inhibitors (adalimumab, infliximab, etanercept) blunt a key inflammatory signal in RA, and rituximab deletes the B cells (anti-CD20) that make autoantibodies. Press Treatment and you will see the attack calm and the organ stabilise — and the infection-risk gauge climb, because a quieter immune system also guards you less well. That trade-off is the central bargain of every autoimmune treatment.
Two important nuances the animation simplifies. First, timing matters: in an organ like the thyroid or pancreas, once enough cells are destroyed the loss is permanent, so calming the attack protects what remains but cannot always regrow what is gone — which is why type 1 diabetes still needs lifelong insulin even with a quiet immune system. Second, not every antibody is destructive in the same way: in Graves’ disease the antibody stimulates the thyroid receptor rather than destroying tissue, so the treatment logic shifts from “suppress the immune system” toward blocking or removing the overactive gland. The general principle — dial the misfire down, weigh it against infection risk — holds throughout.
The myth worth correcting
A common belief is that autoimmune disease means “low immunity” and that you should “boost” your immune system to fix it. It is the opposite. In autoimmunity the immune system is too active and pointed the wrong way; the entire point of treatment is to turn it down, not up. Generic “immune boosters” are the wrong mental model here — and could, in theory, be counter-productive. What genuinely helps is well-studied: taking prescribed immune-modulating medication, not smoking (smoking clearly worsens RA and lupus), treating infections, and keeping the rest of your health strong so you tolerate treatment. The honest message is calmer and more useful than the “boost your immunity” slogan: the goal is balance and precision, not more firepower.